ARIAD Announces Issuance of Key U.S. Patent on Brigatinib
S&P 500 back for another crack at trendline -2-
ARIAD Announces Approval of Iclusig (as Ponatinib Hydrochloride) in Canada
S&P 500's slow-motion breakout attempt remains -2-
UPDATE: S&P 500's slow-motion breakout attempt -2-
These two small-value funds have followed different paths to success in a difficult year for the peer group.